- Dimesna
-
-
2020-07-22
- CAS:16208-51-8
- Min. Order: 1g
- Purity: 99.0%
- Supply Ability: 50kg/month
- Dimesna
-
-
2019-12-26
- CAS:16208-51-8
- Min. Order: 1KG
- Purity: 95%-99%
- Supply Ability: 1kg; 100kg; 1000kg
|
| | Dimesna Basic information |
| Product Name: | Dimesna | | Synonyms: | Mesna EP Impurity D;Disodium 2,2`-dithio-bis-ethane sulphonate;DIMESNA (DISODIUM 2,2'-DITHIOBISETHANE SULFONATE);DIMESNA(SUBJECTTOPATENTFREE);Bis(2-sulfoethyl)disulfide disodium salt;Disodium 2,2'-dithiodiethanesulfonate;2,2'-dithiobis(ethanesulfonic acid), disodium salt;2,2'-Dithiobis(ethanesulfonic acid sodium) salt | | CAS: | 16208-51-8 | | MF: | C4H8Na2O6S4 | | MW: | 326.34 | | EINECS: | 240-337-2 | | Product Categories: | Other APIs;Aliphatics;Sulfur & Selenium Compounds | | Mol File: | 16208-51-8.mol |  |
| | Dimesna Chemical Properties |
| TSCA | TSCA listed | | HS Code | 2930909899 |
| | Dimesna Usage And Synthesis |
| Chemical Properties | White Solid | | Uses | Dimesna (Mesna EP Impurity D) reacts with acrolein and other urotoxic metabolites of oxazaphosphorines (cyclophosphamide or ifosfamide) to form stable, non-urotoxic compounds. Mesna does not have any antitumour activity, nor does it appear to interfere with the antitumour activity of antineoplastic drugs. This medication is used to protect the bladder wall from the harmful effects of some cancer-fighting drugs. | | Uses | Dimesna reacts with acrolein and other urotoxic metabolites of oxazaphosphorines (cyclophosphamide or ifosfamide) to form stable, non-urotoxic compounds. Mesna does not have any antitumour activity, nor does it appear to interfere with the antitumour activity of antineoplastic drugs. This medication is used to protect the bladder wall from the harmful effects of some cancer-fighting drugs. |
| | Dimesna Preparation Products And Raw materials |
|